



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Xiulin Jiang
jiangxiulin@mail.kiz.ac.cn
Mintu Pal
mpal24@yahoo.com

[†]These authors have contributed
equally to this work

SPECIALTY SECTION

This article was submitted to
Thoracic Oncology,
a section of the journal
Frontiers in Oncology

RECEIVED 18 June 2022

ACCEPTED 01 July 2022

PUBLISHED 26 July 2022

CITATION

Li X, Yuan Y, Pal M and Jiang X (2022)
Corrigendum: identification and
validation of lncRNA-SNHG17 in lung
adenocarcinoma: a novel prognostic
and diagnostic indicator.
Front. Oncol. 12:972329.
doi: 10.3389/fonc.2022.972329

COPYRIGHT

© 2022 Li, Yuan, Pal and Jiang. This is
an open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use,
distribution or reproduction is
permitted which does not comply with
these terms.

Corrigendum: identification and validation of lncRNA-SNHG17 in lung adenocarcinoma: a novel prognostic and diagnostic indicator

Xinyan Li^{1†}, Yixiao Yuan^{2†}, Mintu Pal^{3*} and Xiulin Jiang^{4,5*}

¹Department of Pharmacy, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, ²Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China, ³Department of Pharmacology, All India Institute of Medical Sciences (AIIMS) Bathinda, Punjab, India, ⁴Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology, Kunming, China, ⁵Kunming College of Life Science, University of Chinese Academy of Sciences, Beijing, China

KEYWORDS

lung adenocarcinoma, inflammatory response-related gene, DNA methylation, ceRNA, immune cell infiltration, drug sensitivity

A Corrigendum on

Identification and Validation of lncRNA-SNHG17 in Lung Adenocarcinoma: A Novel Prognostic and Diagnostic Indicator

by Li X, Yuan Y, Pal M and Jiang X (2022) *Front. Oncol.* 12:929655.
doi: 10.3389/fonc.2022.929655

In the original article, author Mintu Pal was mistakenly affiliated with - “Biotechnology Division, North East Institute of Science and Technology, Jorhat, India” as published. The correct affiliation should be - “Department of Pharmacology, All India Institute of Medical Sciences (AIIMS) Bathinda, Punjab, India” as above.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.